Oxford Gene Technology Ltd. Sequencing Workshop at European Society of Human Genetics 2011 Attracts Over 130 Delegates

Published: Jul 07, 2011

Oxford, UK – 7th July 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built on a strong foundation of flexibility, expert project design and advanced data reporting, the new offering is focused on providing researchers with clear, prioritised results that are optimised for quick and insightful interpretation. This is achieved by utilising OGT’s internationally recognised probe design and data analysis expertise combined with their independently accredited laboratory processes.

Dr Mike Evans, OGT’s CEO and one of the presenters at the meeting, commented: “We were pleased to see such significant interest in OGT’s new targeted sequencing service. At OGT, we always seek to understand the biological question underlying each experiment and are aware of the data challenges facing the widespread use of next generation technologies. As such, rather than generating complex, insurmountable data sets, our service is specifically designed to deliver meaningful, filtered results.”

As part of the service, researchers can perform whole exome or custom analyses using novel capture probes designed by OGT experts that achieve highly efficient and uniformly distributed target capture. This expands the options available, all of which can be combined seamlessly with other aspects of OGT’s Genefficiency™ Genomic Services to provide the complete solution for genomic research.

To see the presentations from the OGT Workshop and to find out more about Genefficiency Genomic Services, visit www.ogt.co.uk/ESHG2011.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 (0) 1865 856826 ;

F: +44 (0) 1865 848684 ;

E: products@ogt.co.uk

W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Back to news